Q-omics provides the consensus-scored KCTD9P1 profile across patient tissues and cancer cell-line models. KCTD9P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KCTD9P1 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, KCTD9P1 RNA expression shows 11,204 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, BRCA, and THYM as cancer lineages where KCTD9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD9P1 survival associations across molecular data types. KCTD9P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD9P1 RNA expression–survival associations across cancer types. High KCTD9P1 expression shows unfavorable associations in MESO, DLBC, COAD and LGG, but favorable associations in ACC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KCTD9P1 RNA expression.
This table summarizes KCTD9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD9P1 shows lower tumor expression in BRCA and LUAD. The BRCA box plot shows higher KCTD9P1 RNA expression in normal versus tumor tissue (log2 FC = −0.083, t-test p = .001).
This table shows molecular features associated with KCTD9P1 in patient tissues and cancer cell lines. In patient samples, KCTD9P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
